Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aging process is followed by metabolic and body composition changes, increasing the risk of obesity and sarcopenia. The coexistence of these conditions acts synergistically on each other and is known as sarcopenic obesity. Beige adipose tissue is a tissue type that emerges from subcutaneous white adipose tissue (WAT), altering its phenotype to resemble the thermogenic functions of brown adipose tissue (BAT) in response to beta-adrenergic stimuli. Some in vitro and animal studies suggest that taurine supplementation and physical exercise are effective interventions in stimulating the aforementioned tissue, promoting what is known as WAT darkening, improving energy metabolism and showing benefits on the maintenance of muscle mass via stimulation of the coactivating protein PGC1α. These investigations are scarce in humans and could help health professionals in the adjuvant treatment of sarcopenic obesity. Therefore, the aim of the present study is to analyze the effects of taurine supplementation associated or not with physical exercise on the darkening of the WAT in sarcopenic obese elderly women.
The aging process is followed by metabolic and body composition changes, increasing the risk of obesity and sarcopenia. The coexistence of these conditions acts synergistically on each other and is known as sarcopenic obesity. Beige adipose tissue is a tissue type that emerges from subcutaneous white adipose tissue (WAT), altering its phenotype to resemble the thermogenic functions of brown adipose tissue (BAT) in response to beta-adrenergic stimuli. Some in vitro and animal studies suggest that taurine supplementation and physical exercise are effective interventions in stimulating the aforementioned tissue, promoting what is known as WAT darkening, improving energy metabolism and showing benefits on the maintenance of muscle mass via stimulation of the coactivating protein PGC1α. These investigations are scarce in humans and could help health professionals in the adjuvant treatment of sarcopenic obesity. Therefore, the aim of the present study is to analyze the effects of taurine supplementation associated or not with physical exercise on the darkening of the WAT in sarcopenic obese elderly women. Volunteers with low appendicular lean mass (<15 kg) and body mass index (BMI) between 30 and 40 kg/m² will be recruited. These will be subdivided into 4 groups: control group (Cont), taurine (Tau), exercise (Exe) and exercise and taurine (Exe +Tau) and the duration of the intervention for all groups will be 16 weeks. Data related to anthropometry, body composition, biochemical tests, and food intake will be collected. To evaluate the effects on the darkening, a biopsy of the abdominal subcutaneous white adipose tissue will be performed to analyze protein, lipidomic and genetic parameters of this tissue pre and post intervention. Data will be analyzed by Analysis of Variance (ANOVA) or Kruskal-Wallis test depending on the normality of the data that will be tested by Shapiro-Wilk. A significance level for p <0.05 will be admitted. All analyzes will be performed in SPSS version 20 software.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Taurine and Exercise (Tau+Exe) | Experimental | Individuals who will receive 3g of taurine supplementation combined with physical training in the period of 16 weeks |
|
| Taurine (Tau) | Experimental | Individuals who will receive 3g of taurine supplementation |
|
| Exercise (Exe) | Experimental | Individuals who will perform a physical training and receive a placebo supplementation in the period of 16 weeks |
|
| Placebo (Cont) | Placebo Comparator | Individuals who will receive a placebo supplementation in the period of 16 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Taurine supplementation | Dietary Supplement | Participants will receive 3g of taurine to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks. |
| Measure | Description | Time Frame |
|---|---|---|
| Browning of white adipose tissue | Changes in the gene and protein expression on the subcutaneous white adipose tissue | 16 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in metabolic parameters - fasting blood glucose | Changes in fasting blood glucose samples in pre and post intervention | 16 weeks |
| Changes in metabolic parameters - lipid profile | Changes in lipid profile (total cholesterol, HDL-c, LDL-c, triglycerides)samples in pre and post intervention |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Female
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ellen C de Freitas, PhD | University of São Paulo, School of Physical Education and Sports of Ribeirão Preto Ph.D. +55 16 3602-0345 ellenfreitas@usp.br | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Escola de Educação Física e Esporte de Ribeirão Preto | Ribeirão Preto | São Paulo | 14040-907 | Brazil |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Randomized clinical trial.
Not provided
Not provided
Not provided
| Pshysical exercise | Other | Participants will perform a multicomponent type workout that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 16 weeks |
|
| Placebo control | Other | The participants will receive a supplementation capsule containing placebo in the morning in single-dose capsules. The intervention will last 16 weeks. |
|
| 16 weeks |
| Changes in metabolic parameters - insulin sensitivity | Changes in insulin sensitivity samples in pre and post intervention | 16 weeks |
| Body composition changes | Changes in fat-free mass and fat mass evaluated pre and post intervention by iDEXA | 16 weeks |
| Improvement of physical performance | Improvement of physical performance evaluated by the 6-minute walk test, elbow flexion, sit and stand test and hand grip test | 16 weeks |
| Indirect calorimetry assessment | Changes in resting metabolic rate (RMR) evaluated pre and post intervention by indirect calorimetry. | 16 weeks |
| Changes in inflamatory markers | Evaluate the inflamatory markers PCR, IL-1β, IL-6, IL-10, IL-15, IFNy, MCP1, TNF-α, NFκβ, JNK1, PTP1B, iNOS | 16 weeks |
| Changes in subcutaneous white adipose tissue (sWAT) morphology | Evaluate the changes in the white adipose tissue morphology by the histological analysis | 16 weeks |
| Changes in Lipidomic profile of sWAT | Evaluate the fatty acids profile in the sWAT | 16 weeks |
| Changes in plasma taurine | Evaluate the changes in the plasma taurine pre and post intervention | 16 weeks |
| Changes in plasma irisin | Evaluate the changes in plasma irisin pre and post intervention | 16 weeks |
| ID | Term |
|---|---|
| D009765 | Obesity |
| D055948 | Sarcopenia |
| D009043 | Motor Activity |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D009133 | Muscular Atrophy |
| D020879 | Neuromuscular Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D001284 | Atrophy |
| D020763 | Pathological Conditions, Anatomical |
| D001519 | Behavior |
Not provided
Not provided